This is not the most recent version of the article. View current version (6 AUG 2013)
Laquinimod for multiple sclerosis
Published Online: 30 APR 2013
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
He D, Han K, Gao X, Dong S, Chu L, Feng Z, Wu S. Laquinimod for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD010475. DOI: 10.1002/14651858.CD010475.
- Publication Status: New
- Published Online: 30 APR 2013
This is not the most recent version of the article. View current version (06 AUG 2013)
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effectiveness and safety profile of laquinimod as monotherapy or combination therapy versus placebo or approved disease-modifying drugs (DMDs) (IFN-β, glatiramer acetate, natalizumab, mitoxantrone, fingolimod, teriflunomide) for modifying disease course in patients with multiple sclerosis (MS).